

Point by point responses

Major points

1. The authors need to emphasize their own opinions in this manuscript, rather than a simple list of documents. Try to discuss the best individualized treatment plan for different patients with hepatocellular carcinoma and PVTT, write one section clearly to define the problem.

In response to this comment, we did our best to add our own opinions throughout the manuscript.

2. Since outcomes of treatments can be quite different across tumor stages and different location and extent of PVTT, the authors need to review the available evidence supporting the potential roles of different therapeutic strategies in the different stages of HCC.

In response to this comment, we tried to search the latest data supporting the role of different treatment options in HCC and PVTT and revise our manuscript accordingly.

3. The authors have shown the survival benefits of the various therapeutic strategies in patients with advanced HCC with PVTT. However, the authors should also note the tolerance profile.

In response to this comment, we have added the available tolerance profile of the various treatment modalities as much as possible.

4. The conclusion section needs to include the general treatment recommendations for patients with HCC and PVTT.

In response to this comment, we added a separate section dealing with general treatment guideline.

5. The authors described various therapeutic strategies. Could the authors make a

table to summarize and compare these therapeutic strategies?

In response to this comment, we made a table to summarize the outcomes of each

treatment modalities.

Minor points

1. How about drug-eluting bead TACE in patients with HCC and PVTT?

In response to this comment, we performed literature search and added relevant information on DCB TACE.

2. There are several typos such as recurrence rates on page 4, line 12 and cirrohtics on page 8, line 12–13.

In response to this comment, we corrected all the typos in the manuscript.